NHMRC information paper: evidence on the effectiveness of homeopathy for treating health conditions

This paper provides a summary of evidence from research on the effectiveness of homeopathy in treating health conditions in humans. Findings There was no reliable evidence from research in humans that homeopathy was effective for treating the range of health conditions considered: no good-quality, well-designed studies with enough participants for a meaningful result reported either that homeopathy caused greater health improvements than placebo, or caused health improvements equal to those of another treatment. For some health conditions, studies reported that homeopathy was not more effective than placebo. For other health conditions, there were poor-quality studies that reported homeopathy was more effective than placebo, or as effective as another treatment. However, based on their limitations, those studies were not reliable for making conclusions about whether homeopathy was effective. For the remaining health conditions it was not possible to make any conclusion about whether homeopathy was effective or not, because there was not enough evidence. Conclusions Based on the assessment of the evidence of effectiveness of homeopathy, NHMRC concludes that there are no health conditions for which there is reliable evidence that homeopathy is effective. Homeopathy should not be used to treat health conditions that are chronic, serious, or could become serious. People who choose homeopathy may put their health at risk if they reject or delay treatments for which there is good evidence for safety and effectiveness. People who are considering whether to use homeopathy should first get advice from a registered health practitioner. Those who use homeopathy should tell their health practitioner and should keep taking any prescribed treatments

Influence of therapist competence and quantity of cognitive behavioural therapy on suicidal behaviour and inpatient hospitalisation in a randomised controlled trial in borderline personality disorder: Further analyses of treatment effects in the BOSCOT study

<br>Objectives. We investigated the treatment effects reported from a high-quality randomized controlled trial of cognitive behavioural therapy (CBT) for 106 people with borderline personality disorder attending community-based clinics in the UK National Health Service – the BOSCOT trial. Specifically, we examined whether the amount of therapy and therapist competence had an impact on our primary outcome, the number of suicidal acts, using instrumental variables regression modelling. Design. Randomized controlled trial. Participants from across three sites (London, Glasgow, and Ayrshire/Arran) were randomized equally to CBT for personality disorders (CBTpd) plus Treatment as Usual or to Treatment as Usual. Treatment as Usual varied between sites and individuals, but was consistent with routine treatment in the UK National Health Service at the time. CBTpd comprised an average 16 sessions (range 0–35) over 12 months.</br> <br>Method. We used instrumental variable regression modelling to estimate the impact of quantity and quality of therapy received (recording activities and behaviours that took place after randomization) on number of suicidal acts and inpatient psychiatric hospitalization.</br> <br>Results. A total of 101 participants provided full outcome data at 2 years post randomization. The previously reported intention-to-treat (ITT) results showed on average a reduction of 0.91 (95% confidence interval 0.15–1.67) suicidal acts over 2 years for those randomized to CBT. By incorporating the influence of quantity of therapy and therapist competence, we show that this estimate of the effect of CBTpd could be approximately two to three times greater for those receiving the right amount of therapy from a competent therapist.</br> <br>Conclusions. Trials should routinely control for and collect data on both quantity of therapy and therapist competence, which can be used, via instrumental variable regression modelling, to estimate treatment effects for optimal delivery of therapy. Such estimates complement rather than replace the ITT results, which are properly the principal analysis results from such trials.</br&gt

Health communication implications of the perceived meanings of terms used to denote unhealthy foods

Background: Using appropriate terminology in nutrition education programs and behaviour change campaigns is important to optimise the effectiveness of these efforts. To inform future communications on the topic of healthy eating, this study explored adults’ perceptions of the meaning of four terms used to describe unhealthy foods: junk food, snack food, party food, and discretionary food. Methods: Australian adults were recruited to participate in an online survey that included demographic items and open-ended questions relating to perceptions of the four terms. In total, 409 respondents aged 25–64 years completed the survey. Results: ‘Junk food’ was the term most clearly aligned with unhealthiness, and is therefore likely to represent wording that will have salience and relevance to many target audience members. Snack foods were considered to include both healthy and unhealthy food products, and both snack foods and party foods were often described as being consumed in small portions. Despite being used in dietary guidelines, the term ‘discretionary food’ was unfamiliar to many respondents. Conclusions: These results demonstrate that different terms for unhealthy foods can have substantially different meanings for audience members. A detailed understanding of these meanings is needed to ensure that nutrition guidance and health promotion campaigns use appropriate terminology

Prevalence of drug resistance in patients with pulmonary tuberculosis presenting for the first time with symptoms at chest clinics in India. Part 2. Findings in urban clinics among all patients with or without history of previous chemotherapy

A previous report (Indian Council of Medical Research First Drug Resistance Investigation, 1968) presented the results of a co-operative investigation on the prevalence of drug resistance in patients with pulmonary tuberculosis, presenting for the first time with symptoms at chest clinics in India and giving no history of previous antituberculosis chemotherapy. However, the information obtained from that investigation is of rather limited value because, in most clinics, fairly large proportions of patients reporting for the first time do so with a history of previous treatment. This is because antituberculosis chemotherapy is offered not only by chest clinics, but also by general hospitals and private practitioners. In these circumstances, information on the prevalence of drug resistance among all patients, irrespective of the history of previous antituberculosis chemotherapy, will be of great value, not only to the cliniciansin- charge of the chest clinics but also to those responsible for formulating general policies of treatment in the country. The second drug resistance investigation was undertake

Prevalence of drug resistance in patients with pulmonary tuberculosis presenting for the first time with symptoms at chest clinics in India. 1. Findings in urban clinics among patients giving no history of previous chemotherapy

IT is generally accepted that information on the prevalence of drug resistance is essential for countries which contemplate mass chemotherapy programme for tuberculosis (International Union against Tuberculosis, 1961). In India in 1964, information on this subject was confined to certain limited areas only (Tuberculosis Chemotherapy Centre, Madras, 1959, 1960, 1964 ; Frimodt-Moller, 1962 ; Menon, 1963 ; Balbir Singh, 1964). Therefore, the Indian Council of Medical Research (I.C.M.R.) launched a series of investigations to determine the prevalence of drug resistance in tuberculous patients reporting for the first time with symptoms at chest clinics ; chest clinics were chosen since they are an obvious starting point for any mass chemotherapy programme. A special sub-committee of the Indian Council of Medical Research (see footnote) was constituted to organise the execution of these investigations, and a Central Laboratory set up on the premises of the Tuberculosis Chemotherapy Centre, Madras, to undertake all the necessary bacteriological investigations

Information paper: evidence on wind farms and human health

This Information Paper provides Australians with a summary of the evidence on possible health effects of wind farms in humans and explains how NHMRC developed its summary based on the findings of independent reviews of the evidence. It is intended for use by any person or group interested in wind farms. Wind farms in Australia Wind turbines use rotating blades attached to towers to convert wind energy into electricity. A group of wind turbines is known as a wind farm and may be located on land or offshore. Wind turbine design has evolved over the last 20 years to enable better harnessing of wind energy. Wind farms have been promoted as a viable and sustainable alternative to traditional, non-renewable forms of energy production. Since the introduction of the Renewable Energy Act 2000, the number of wind farms in Australia has grown substantially. At the end of 2013, there were 68 wind farms across the country and more were being constructed or planned. Why NHMRC is conducting this work NHMRC is responsible for ensuring that Australians receive the best available, evidence-based advice on matters relating to improving health and to preventing, diagnosing and treating disease. Concern about the effects on health from living near a wind farm has been expressed by some members of the community. Therefore, NHMRC examined the evidence on health effects associated with exposure to specific emissions from wind farms — noise, shadow flicker and electromagnetic radiation. The current investigation of the potential health effects of wind farms builds upon NHMRC’s previous work in this area. In 2010, NHMRC’s Public statement: Wind turbines and health was published, with supporting evidence from Wind turbines and health: A rapid review of the evidence. The 2010 NHMRC Public Statement concluded that there “is currently no published scientific evidence to positively link wind turbines with adverse health effects”. Due to the limited amount of published scientific literature, NHMRC committed to carrying out a more extensive search for evidence. This Information Paper provides an update to NHMRC’s previous work in this area. It is based on a comprehensive review of the available scientific evidence following well-established systematic review principles, which provide the most rigorous process for identifying and critically appraising evidence. In Australia, responsibility for regulating the planning, development and operation of wind farms lies with state, territory and local governments. The outcomes of NHMRC’s review may assist these organisations to make decisions about the regulation of wind farms. NHMRC’s review of the evidence will enable well-designed and targeted research to be undertaken in areas that have been identified as gaps in the evidence base

Lactate signalling regulates fungal β-glucan masking and immune evasion

AJPB: This work was supported by the European Research Council (STRIFE, ERC- 2009-AdG-249793), The UK Medical Research Council (MR/M026663/1), the UK Biotechnology and Biological Research Council (BB/K017365/1), the Wellcome Trust (080088; 097377). ERB: This work was supported by the UK Biotechnology and Biological Research Council (BB/M014525/1). GMA: Supported by the CNPq-Brazil (Science without Borders fellowship 202976/2014-9). GDB: Wellcome Trust (102705). CAM: This work was supported by the UK Medical Research Council (G0400284). DMM: This work was supported by UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/K000306/1). NARG/JW: Wellcome Trust (086827, 075470,101873) and Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology (097377). ALL: This work was supported by the MRC Centre for Medical Mycology and the University of Aberdeen (MR/N006364/1).Peer reviewedPostprin

Replication-Coupled PCNA Unloading by the Elg1 Complex Occurs Genome-wide and Requires Okazaki Fragment Ligation

Open Access funded by Medical Research Council Acknowledgments We thank Dr Anja Bielinsky for plasmids and Dr. M.K. Raghuraman for a cdc9-1 strain. Alexander Lorenz (University of Aberdeen) provided valuable comments on the manuscript. This work was supported by Biotechnology and Biological Sciences Research Council (BBSRC) grant BB/K006304/1 to A.D., Medical Research Council Career Development Fellowship MR/L019698/1 to T.K., and MEXT Grant-in-Aid for Scientific Research on Innovative Areas to K.S.Peer reviewedPublisher PD

The Medical Research Council

Click on the link to view the editorial